The Medicines and Healthcare products Regulatory Agency (MHRA) has approved (27 December 2024) the medicine sotatercept ...

The Medicines and Healthcare products Regulatory Agency (MHRA) has today, 31 December 2024, approved the medicine tarlatamab ...

The UK Medicines and Healthcare products Regulatory Agency (MHRA) isn't sufficiently funded to meet its obligations, according to a new report commissioned by a pharma trade organisation.

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has announced the five technologies selected to participate in the ‘AI Airlock Pilot’ for AI-powered medical devices.

The UK’s Medicines and Healthcare products Regulatory Agency (MHRA) has announced sweeping changes to regulations governing clinical trials, which it says are the largest in more than 20 years.

Five AI technologies have been selected by the Medicines and Healthcare products Regulatory Agency (MHRA) for its AI Airlock pilot scheme for medical devices. The scheme is aimed at building ...

John Marshall used to enjoy running but after a serious reaction to antibiotics in 2017 he was left barely able to walk. The 51-year-old from Kirkcaldy says his health changed dramatically after just ...

LEO Pharma has gained marketing authorisation from the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, Anzupgo (delgocitinib ...

today announced that the U.K. Medicines & Healthcare Products Regulatory Agency (MHRA) has granted Innovation Passport designation to BPZE1, the leading next generation intranasal pertussis vaccine.

Credit: Kmpzzz/Shutterstock. Leo Pharma has gained marketing authorisation from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) for its topical pan-Janus kinase (JAK) inhibitor, ...

The Medicines and Healthcare Products Regulatory Agency (MHRA) has granted marketing authorisation in Great Britain for Anzupgo ® (delgocitinib) 20mg/g cream for the treatment of adult patients with ...

More than 80 per cent of respondents involved in investment decisions said the MHRA’s “capacity and predictability” was the biggest factor deterring investment in manufacturing or clinical ...